These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12952507)

  • 1. Immunosuppresive therapy for inflammatory bowel disease.
    Casis Herce B
    Rev Esp Enferm Dig; 2003 Jul; 95(7):456-8, 453-5. PubMed ID: 12952507
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical therapy of IBD in 2009.
    Harris A; Feller ER; Shah SA
    Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X; Phelip JM
    Arch Intern Med; 2008 Mar; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract]   [Full Text] [Related]  

  • 4. Methotrexate in inflammatory bowel disease.
    Feagan BG; Alfadhli A
    Gastroenterol Clin North Am; 2004 Jun; 33(2):407-20, xi. PubMed ID: 15177546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 6. General principles of medical therapy of inflammatory bowel disease.
    Friedman S
    Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the use of non-biologic agents in the treatment of inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():86-90. PubMed ID: 17037785
    [No Abstract]   [Full Text] [Related]  

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal antibody use in inflammatory bowel disease.
    Hayes CE; Cerezo CS
    Med Health R I; 2011 Nov; 94(11):337-40. PubMed ID: 22204097
    [No Abstract]   [Full Text] [Related]  

  • 12. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of inflammatory bowel disease.
    Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):xv-xvi. PubMed ID: 15177548
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug therapy of chronic inflammatory bowel diseases: what is new?].
    Stange EF
    Z Gastroenterol; 2002 Dec; 40 Suppl 2():71-2. PubMed ID: 12467016
    [No Abstract]   [Full Text] [Related]  

  • 16. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
    Kwon JH; Farrell RJ
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic role of thalidomide in inflammatory bowel disease.
    Casella G; De Marco E; Monti C; Baldini V
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):293-301. PubMed ID: 16971873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of the pregnant patient with inflammatory bowel disease.
    Steinlauf AF; Present DH
    Gastroenterol Clin North Am; 2004 Jun; 33(2):361-85, xi. PubMed ID: 15177544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
    Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.